Investigating a receptor's role in abdominal aortic aneurysms
The role of protease activated receptor 2 in the initiation and progression of abdominal aortic aneurysm
This study is looking at how a specific protein called PAR2 affects the growth and worsening of abdominal aortic aneurysms, with the goal of finding new treatment options for patients beyond just surgery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-11121653 on NIH RePORTER |
What this research studies
This research focuses on understanding how protease-activated receptor 2 (PAR2) contributes to the development and worsening of abdominal aortic aneurysms (AAA). The study aims to explore the mechanisms by which PAR2 influences vascular inflammation and the behavior of specific immune cells in the aorta. By examining the effects of PAR2 on aortic health, the research seeks to identify potential new treatment options beyond surgery for patients suffering from AAA. Patients may be involved in the research to help uncover the biological pathways that lead to this serious condition.
Who could benefit from this research
Good fit: Ideal candidates for this research include older adults, particularly those over the age of 65, who are at higher risk for developing abdominal aortic aneurysms.
Not a fit: Patients under the age of 65 or those without risk factors for abdominal aortic aneurysms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new pharmacologic treatments for abdominal aortic aneurysms, potentially reducing the need for surgical interventions.
How similar studies have performed: While the role of PAR2 in cardiovascular diseases is being explored, this specific investigation into its role in abdominal aortic aneurysms is relatively novel and has not been extensively tested.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Owens Iii, Albert Phillip — University of Cincinnati
- Study coordinator: Owens Iii, Albert Phillip
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.